Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
916
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Blood MALT1 deficiency is common and relates to unfavorable induction therapy response and survival profile in acute myeloid leukemia patients

Haili GengFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of ChinaView further author information
,
Yiting WangFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of ChinaView further author information
&
Shaoyuan WangFujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 1176-1183 | Published online: 31 Oct 2022

References

  • Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J. 2020 Apr 1;103(3):38–40.
  • Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7–33.
  • Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019 Jul;36:70–87.
  • Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021 Feb 22;11(2):41.
  • Ciftciler R, Demiroglu H, Haznedaroglu IC, et al. Impact of time between induction chemotherapy and complete remission on survival outcomes in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):729–734.
  • Yoo KH, Kim HJ, Min YH, et al. Age and remission induction therapy for acute myeloid leukemia: an analysis of data from the Korean acute myeloid leukemia registry. PLoS One. 2021;16(5):e0251011.
  • Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020 Jun 29;21(8):66.
  • Lork M, Staal J, Beyaert R. Ubiquitination and phosphorylation of the CARD11-BCL10-MALT1 signalosome in T cells. Cell Immunol. 2019 Jun;340:103877.
  • Rosenbaum M, Gewies A, Pechloff K, et al. Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. Nat Commun. 2019 May 28;10(1):2352.
  • Martin K, Touil R, Kolb Y, et al. Malt1 protease deficiency in mice disrupts immune homeostasis at environmental barriers and drives systemic T cell-mediated autoimmunity. J Immunol. 2019 Dec 1;203(11):2791–2806.
  • Ishikawa C, Mori N. MALT-1 as a novel therapeutic target for adult T-cell leukemia. Eur J Haematol 2020 Oct;105(4):460–467.
  • Dumont C, Sivars U, Andreasson T, et al. A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1/regulatory T-cell homeostasis. PLoS One. 2020;15(9):e0222548.
  • Wang R, Zhang H, Xu J, et al. Malt1 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia by blocking Notch1-induced NF-κB activation. Front Oncol. 2020;10:558339.
  • Saba NS, Wong DH, Tanios G, et al. Malt1 inhibition is efficacious in both naïve and ibrutinib-resistant chronic lymphocytic leukemia. Cancer Res 2017 Dec 15;77(24):7038–7048.
  • Ma Y, Liao Z, Xu Y, et al. Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia. Eur J Med Res 2014 Nov 11;19:62.
  • Xu Y, Hu J, Wang X, et al. Overexpression of MALT1-A20-NF-κB in adult B-cell acute lymphoblastic leukemia. Cancer Cell Int. 2015;15:73.
  • Wang X, Xu Y, Liang L, et al. Abnormal expression of A20 and its regulated genes in peripheral blood from patients with lymphomas. Cancer Cell Int. 2014;14:36.
  • NCCN clinical practice guidelines in oncology on acute myeloid leukemia version 1. (2017). (available at www.nccn.org).
  • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001 Dec;25(4):402–408.
  • Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453–474.
  • Shi L, Chen S, Lu Y, et al. Changes in the MALT1-A20-NF-κB expression pattern may be related to T cell dysfunction in AML. Cancer Cell Int. 2013 Apr 30;13(1):37.
  • Gehring T, Erdmann T, Rahm M, et al. Malt1 phosphorylation controls activation of T lymphocytes and survival of ABC-DLBCL tumor cells. Cell Rep. 2019 Oct 22;29(4):873–888 e10.
  • Cheng J, Klei LR, Hubel NE, et al. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein. J Clin Invest. 2020 Feb 3;130(2):1036–1051.
  • Dai B, Grau M, Juilland M, et al. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood. 2017 Jan 19;129(3):333–346.
  • Lu HY, Turvey SE. Human MALT1 deficiency and predisposition to infections. Curr Opin Immunol. 2021 Oct;72:1–12.
  • Shafat MS, Gnaneswaran B, Bowles KM, et al. The bone marrow microenvironment - home of the leukemic blasts. Blood Rev. 2017 Sep;31(5):277–286.
  • Percival ME, Lai C, Estey E, et al. Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Rev. 2017 Jul;31(4):185–192.
  • Zhang S, Pan D, Jia XM, et al. The CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-κB activation and cell survival. Protein Cell. 2017 Nov;8(11):856–860.
  • Upadhyay VA, Fathi AT. Induction chemotherapy in acute myeloid leukaemia. Curr Opin Hematol. 2018 Mar;25(2):67–74.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.